Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes
Authors' conclusion
Aspirin therapy for primary prevention of CVD has decreased over the last two decades. However, the drug remained used in individuals with and without diabetes, and a large proportion of individuals started on aspirin therapy had no CVD risk factors.
Study context
- Population
- Danish adults ≥40 years without cardiovascular disease (CVD) eligible for primary preventive aspirin therapy, 2000–2020
- Participants
- 522,680 incident aspirin users
- Exposure
- Diabetes vs no diabetes
- Outcome
- Temporal trends in primary prevention aspirin use (incident and prevalent users)
- Follow-up
- 2000 through 2020
Methodological detailsDanish nationwide registries, 2000–2020
- Danish nationwide registries
- 2000–2020
Main finding
As reported in the abstract
- Incident users peak in 2002: 39 803 individuals
- 1.78%
- Incident users lowest in 2019: 11 898 individuals
- 0.49%
- Prevalent users peak in 2008
- 7.7%
- Prevalent users in 2020
- 3.3%
- Prevalent users with diabetes, peak in 2009
- 38.5%
- Prevalent users with diabetes in 2020
- 17.1%
Observational data: associations, not effects.
Further findings
Incident users with no CVD risk factors (diabetes, hypertension, hypercholesterolemia or COPD as smoking proxy)
- 2000
- 53.9%
- 2020
- 30.9%
Original publication
Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. Eur J Prev Cardiol. Published 22 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →